Clinical trials
General Population (no Specific Condition or Disease) clinical trials
Below are recruiting general population (no specific condition or disease) clinical trials, each written for real people, not researchers. We’re tracking 10,579 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05454774RecruitingEarly Phase 1
Gene therapy for adults with severe hemophilia A
This early-phase study tests an FVIII gene therapy to help your body make more of the missing clotting factor in hemophilia A. It’s aimed at adults with severe low FVIII levels who have already used FVIII replacement products for a long time and have not developed an immune blocker (an inhibitor).
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT06836882Recruiting
Testing cavity disinfectants for deep tooth decay pain
This study tests two cavity disinfectants to see which one better reduces pain and improves healing after removing deep decay from back teeth. It is for adults with deep cavities in their lower molars that are still alive (not needing a root canal).
HaryānaAges 18 years+ - NCT06836206RecruitingPhase 1/Phase 2
Gum arabic and kidney function in dialysis patients
This trial tests if taking gum arabic, a natural fiber, can help preserve the remaining kidney function in adults on dialysis. If you produce at least 200 ml of urine a day, this study might help you learn about a possible way to protect your kidneys.
Abu DhabiAges 18 years+ - NCT04839757Recruiting
Testing a dengue vaccine plan for kids in the Caribbean
This trial looks at a dengue vaccine strategy in children ages 9 to 17 in Martinique and Guadeloupe. It may help protect kids from dengue, based on how the vaccine is accepted and how the study is carried out.
Fort-de-FranceAges 9–17 - NCT05709288RecruitingPhase 1
Gene therapy for teens with hemophilia B
This Phase 1 study tests a one-time gene therapy treatment (BBM-H901) for boys ages 12 to 18 with hemophilia B. It aims to see if the treatment is safe and can help the body make more clotting factor over time.
Tianjin, Tianjin MunicipalityAges 12–18 - NCT06839846Recruiting
Survey of weaning methods in babies
This survey asks parents of babies aged 4 to 18 months about how they stopped breastfeeding or bottle-feeding (weaning). It helps doctors understand different weaning methods used by families in Italy.
Imola, BolognaAges Any age - NCT06075420Recruiting
Shorter blood thinner use after GENOSS stent in heart disease
This trial tests whether a shorter course of dual antiplatelet therapy (two blood thinners) is safe and effective for people who have received a GENOSS stent for coronary artery disease. It aims to reduce the risk of bleeding while still preventing heart attacks.
Wŏnju, Gangwon StateAges 19 years+ - NCT06014775RecruitingPhase 2
Anti-CD38 Antibody for Evans syndrome
This trial tests a new drug called an anti-CD38 antibody for people with Evans syndrome, a rare condition where the immune system attacks blood cells. It is for adults whose disease is active and hasn't improved with standard treatments.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT06238908RecruitingEarly Phase 1
Gene therapy NGGT003 for severe hemophilia A
This early-phase trial tests a new gene therapy called NGGT003 for men with severe hemophilia A. It aims to see if the treatment is safe and can help reduce bleeding episodes.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT06529848Recruiting
Exercise for heart symptoms with clear arteries
This trial tests if exercise training can help people who have chest pain or shortness of breath even though their main heart arteries are not blocked. It focuses on those with small vessel disease in the heart, also known as INOCA.
CopenhagenAges 50 years+ - NCT06839755Recruiting
Stress echo's positive value in heart health
This study looks at how well a stress echocardiogram (heart ultrasound during exercise or medication) predicts future health in people who have some sign of reduced blood flow to the heart. The goal is to confirm that a positive stress echo is a good sign for guiding next steps.
Athens, AtticaAges 18–100 - NCT04600960RecruitingPhase 2
Eltrombopag to raise low platelets after chemotherapy
This Phase 2 study tests eltrombopag to help people with low platelet counts caused by chemotherapy (which can increase bleeding risk). It looks at whether raising platelets can reduce bleeding problems and help you stay on track with care.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT04890041Recruiting
Testing TPO medicines for immune low platelets in teens
This trial studies whether “TPO” medicines (like eltrombopag or similar drugs) help people age 14 and older with primary immune thrombocytopenia (ITP) who did not respond well to first treatments. It may help raise platelet counts and reduce bleeding, especially when prior therapy hasn’t worked.
Tianjin, Tianjin MunicipalityAges 14 years+ - NCT05199909RecruitingPhase 2
Testing zanubrutinib for antiphospholipid syndrome with low platelets
This Phase 2 study tests zanubrutinib, a medicine for the immune system, to treat antiphospholipid syndrome when it causes very low platelet counts. It looks at safety and whether it can improve blood clotting problems and low platelets when prior steroid treatment didn’t work well.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT05236582RecruitingPhase 2
Herombopag for low platelets from chemotherapy side effects
This Phase 2 trial studies herombopag to raise very low platelet counts caused by chemotherapy and reduce bleeding risk. It may help people whose platelet levels stay too low even after prior standard attempts like rhTPO or IL-11.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT05214391RecruitingPhase 2
Zanubrutinib for chronic immune low platelets after prior treatments
This Phase 2 study looks at zanubrutinib, a new medication, in people with immune thrombocytopenia (ITP) whose low platelet count has lasted more than 3 months and has not responded to prior steroid and other treatments. It may help raise platelets and reduce bleeding risk when other therapies have not worked.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT05641610RecruitingPhase 1/Phase 2
Study drug for adults with hemophilia B who still bleed
This Phase 1/2 study tests ZS801, a gene-related treatment, to see how safe it is and whether it helps prevent bleeding in adults with hemophilia B. You may be considered if you’ve had frequent bleeds or joint problems and meet several lab and health requirements.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT05630651Recruiting
ZS801 for adults with severe hemophilia B
This trial studies ZS801, a gene therapy, in adults with hemophilia B who have very low natural FIX (a clotting protein) and frequent bleeding or joint problems. It aims to see how well it works and whether it is safe, especially by monitoring blood counts, infections, and immune responses.
Tianjin, Tianjin MunicipalityAges 18–65 - NCT05888870RecruitingPhase 4
Testing a treatment for hemophilia A with inhibitor antibodies
This study tests a therapy called ITI (using SCT800 alone or with daratumumab) to help people with hemophilia A who have inhibitor antibodies that reduce bleeding treatments from working. It may be an option if you’re an adolescent or adult with a high inhibitor level and have not already failed this kind of immune “ITI” treatment before.
TianjinAges 14–65 - NCT06281327RecruitingPhase 2
Avatrombopag for children with ITP switching from eltrombopag
This trial tests a new platelet-raising medicine, avatrombopag, in children with ITP who have already tried eltrombopag. It aims to see if switching to avatrombopag can safely increase platelet counts and reduce bleeding.
TianjinAges 6–18 - NCT06094881RecruitingPhase 2
Obinutuzumab for teens with immune thrombocytopenia
This trial tests a drug called obinutuzumab for teens aged 12–18 with persistent or chronic immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding. The study aims to see if obinutuzumab can safely raise platelet counts in those who haven't responded well to steroids or other treatments.
TianjinAges 12–18 - NCT07376486Recruiting
Early treatment for type 2 diabetes using a new duodenal procedure
This study tests a new procedure called pulsENDO, which is done in the first part of the small intestine (the duodenum) to help treat type 2 diabetes. It may be an option for people who were recently diagnosed and have good blood sugar control with little or no diabetes medication.
ShatinAges 18–60 - NCT07374874Recruiting
Heart and nervous system health after stem cell transplant
This study looks at how your autonomic nervous system (the part that controls heartbeat and digestion) affects the risk of graft-versus-host disease (a condition where donor cells attack your body) after a half-matched stem cell transplant. You may be able to join if you are older than 16 and receiving a half-matched transplant from a family donor.
Tianjin, Tianjin MunicipalityAges 16 years+ - NCT07375953RecruitingPhase 2
Repeated clot-busting drug for stroke within 3 hours
This trial tests if giving a second dose of a clot-busting drug (tenecteplase) helps people who had a stroke and didn't improve much after the first dose. You must receive the second dose within 4.5 hours of your stroke symptoms starting.
Shenyang, None SelectedAges 18–80
Hear when a new General Population (no Specific Condition or Disease) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for general population (no specific condition or disease)?
- Yes. Clin2 currently lists 10,579 recruiting general population (no specific condition or disease) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a general population (no specific condition or disease) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a general population (no specific condition or disease) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.